Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Meihua International Medical Technologies Co., Ltd. (MHUA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Meihua files annual reports on Form 20-F and current reports on Form 6-K under Commission File Number 001-41291, covering its operations as a manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China.
Through its Form 6-K filings, the company reports a range of material events. These include unaudited condensed consolidated financial statements and management’s discussion and analysis for interim periods, such as the six months ended June 30, 2025, which are incorporated by reference into its registration statements. Other 6-K filings describe private placements of ordinary shares to non-U.S. investors under Regulation S, including agreements to sell tens of millions of ordinary shares and subsequent closings, with stated uses of proceeds for working capital and general corporate purposes.
Corporate governance and capital structure changes are also documented in MHUA’s SEC filings. A Form 6-K dated November 18, 2025 details the results of an extraordinary general meeting where shareholders approved a one-for-one-hundred share consolidation, an increase in authorized share capital and the creation of a dual-class share structure with Class A and Class B ordinary shares, along with the adoption of a 2025 equity incentive plan. Another filing from October 2025 furnishes the notice and proxy materials for that extraordinary general meeting. A separate Form 6-K dated August 21, 2025 reports the resignation of the then chief executive officer, chief financial officer and a director, and the appointment of new executives and an independent director, including information on their roles and compensation arrangements.
Auditor changes and listing-related matters also appear in the filings. In a Form 6-K filed on January 7, 2026, Meihua discloses the dismissal of Kreit & Chiu CPA LLP and the appointment of Li CPA LLC as its independent registered public accounting firm for the year ended December 31, 2025, stating that there were no disagreements with the former auditor. Other filings reference the company’s registration statements on Forms F-3 and F-1 and the incorporation by reference of financial statements and XBRL data.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the key points in each document, helping users quickly understand topics such as share structure changes, private placements, management transitions and auditor appointments. Real-time updates from EDGAR ensure that new Forms 20-F and 6-K, as well as exhibits like proxy statements and financial statements, are available as soon as they are filed. Users interested in MHUA can use this page to review the company’s regulatory history, analyze how it describes its financial condition and capital markets transactions, and monitor ongoing corporate and governance developments.
Meihua International Medical Technologies announced major leadership changes, with its chief executive officer, chief financial officer, and a board member all resigning on August 15, 2025, each citing personal reasons and no disagreements over operations, policies, or practices. On the same day, the board appointed Leyi Lee as the new CEO and director, Shilong Liao as the new CFO, and Anna Colin as an independent director.
Ms. Lee will receive annual compensation of $60,000 for her CEO and board roles, and brings prior leadership experience in sales and commercial strategy at several healthcare and AI companies. Mr. Liao will receive annual compensation of $48,000 as CFO and has held senior finance roles, including at Siemens Healthineers. Ms. Colin will be compensated $1,500 per month as an independent director, has a background in operations at major financial institutions, and will chair the Compensation Committee and serve on the Audit and Nominating and Corporate Governance Committees.